Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Sells $24,668.28 in Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso sold 3,012 shares of the stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $8.19, for a total transaction of $24,668.28. Following the completion of the transaction, the chief executive officer now owns 28,537 shares in the company, valued at $233,718.03. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Precision BioSciences Stock Performance

Precision BioSciences stock opened at $8.46 on Wednesday. The company has a market capitalization of $61.17 million, a P/E ratio of 40.69 and a beta of 1.71. Precision BioSciences, Inc. has a fifty-two week low of $7.97 and a fifty-two week high of $19.43. The stock has a 50-day simple moving average of $9.34 and a 200-day simple moving average of $10.06.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of Precision BioSciences in a research report on Thursday, August 22nd.

Institutional Investors Weigh In On Precision BioSciences

A hedge fund recently bought a new stake in Precision BioSciences stock. Janus Henderson Group PLC bought a new position in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 573,052 shares of the company’s stock, valued at approximately $7,739,000. Janus Henderson Group PLC owned about 8.29% of Precision BioSciences at the end of the most recent quarter. 37.99% of the stock is owned by institutional investors.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.